Condition: Ovarian Carcinoma · First Line Chemotherapy · Digestive System Disorders · Sponsor: Centre Francois Baclesse
Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS
This description comes directly from the study's public registry record.
François CHERIFI, Medical Doctor · 0231455050 · f.cherifi@baclesse.unicancer.fr
Always discuss trial participation with your own doctor first.
| Centre François Baclesse | Caen, France | Recruiting |
| CHU CAEN | Caen, France | Not Yet Recruiting |
| Centre Oscar Lambret | Lille, France | Not Yet Recruiting |
| Centre Henri Becquerel | Rouen, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06817161